MSICS Pharma

Company Overview

Snapshot

Founded in April 2022 by Roei Zerahia and Omer Zerahia, MSICS Pharma operates with 11–50 employees. The company has raised $3.7 million across three funding rounds from five investors.

Business overview

MSICS Pharma is an Israeli pioneer in the production of naturally-sourced psilocybin for pharmaceutical applications. The company has established a GMP production facility and is navigating a unique approval process, leveraging its experience with cannabis. MSICS Pharma's psilocybin products are being prepared for clinical trials with hospitals to treat conditions such as OCD, anorexia, PTSD, and depression. The company aims to approve its products as prescribed medicine, starting in Israel and expanding globally to address unmet medical needs within the health tech and life sciences sectors, specifically focusing on drugs discovery and development.

Strategic signal

In May 2026, MSICS Pharma announced its advancement into clinical trials for PTSD, depression, and OCD, following a funding round with participation from. This development signals a critical step forward in validating naturally-sourced psilocybin as a therapeutic agent, positioning the company to address significant mental health challenges within a multi-billion dollar market. For investors, this indicates strong progress in product development and regulatory navigation, potentially de-risking future commercialization efforts.

Company Intelligence Q&A

What is MSICS Pharma's primary focus?

MSICS Pharma focuses on the GMP production of naturally-sourced psilocybin for pharmaceutical use, aiming to develop prescribed medicines for mental health conditions.

When was MSICS Pharma founded and by whom?

MSICS Pharma was founded in April 2022 by Roei Zerahia and Omer Zerahia.

What clinical trials is MSICS Pharma advancing?

MSICS Pharma is advancing clinical trials for conditions such as PTSD, depression, and OCD, with its psilocybin products.